Search tips
Search criteria 


Logo of jvirolPermissionsJournals.ASM.orgJournalJV ArticleJournal InfoAuthorsReviewers
J Virol. 1993 July; 67(7): 4104–4113.
PMCID: PMC237779

Simian immunodeficiency virus mutants resistant to serum neutralization arise during persistent infection of rhesus monkeys.


We previously described the pattern of sequence variation in gp120 following persistent infection of rhesus monkeys with the pathogenic simian immunodeficiency virus SIVmac239 molecular clone (D.P.W. Burns and R.C. Desrosiers, J. Virol. 65:1843, 1991). Sequence changes were confined largely to five variable regions (V1 to V5), four of which correspond to human immunodeficiency virus type 1 (HIV-1) gp120 variable regions. Remarkably, 182 of 186 nucleotide substitutions that were documented in these variable regions resulted in amino acid changes. This is an extremely nonrandom pattern, which suggests selective pressure driving amino acid changes in discrete variable domains. In the present study, we investigated whether neutralizing-antibody responses are one selective force responsible at least in part for the observed pattern of sequence variation. Variant env sequences called 1-12 and 8-22 obtained 69 and 93 weeks after infection of a rhesus monkey with cloned SIVmac239 were recombined into the parental SIVmac239 genome, and variant viruses were generated by transfection of cultured cells with cloned DNA. The 1-12 and 8-22 recombinants differ from the parental SIVmac239 at 18 amino acid positions in gp120 and at 5 and 10 amino acid positions, respectively, in gp41. Sequential sera from the monkey infected with cloned SIVmac239 from which the 1-12 and 8-22 variants were isolated showed much higher neutralizing antibody titers to cloned SIVmac239 than to the cloned 1-12 and 8-22 variants. For example, at 55 weeks postinfection the neutralizing antibody titer against SIVmac239 was 640 while those to the variant viruses were 40 and less than 20. Two other rhesus monkeys infected with cloned SIVmac239 showed a similar pattern. Rhesus monkeys were also experimentally infected with the cloned variants so that the type-specific nature of the neutralizing antibody responses could be verified. Indeed, each of these monkeys showed neutralizing-antibody responses of much higher titer to the homologous variant used for infection. These experiments unambiguously demonstrate that SIV mutants resistant to serum neutralization arise during the course of persistent infection of rhesus monkeys.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (2.0M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Images in this article

Click on the image to see a larger version.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Albert J, Abrahamsson B, Nagy K, Aurelius E, Gaines H, Nyström G, Fenyö EM. Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera. AIDS. 1990 Feb;4(2):107–112. [PubMed]
  • Berman PW, Matthews TJ, Riddle L, Champe M, Hobbs MR, Nakamura GR, Mercer J, Eastman DJ, Lucas C, Langlois AJ, et al. Neutralization of multiple laboratory and clinical isolates of human immunodeficiency virus type 1 (HIV-1) by antisera raised against gp120 from the MN isolate of HIV-1. J Virol. 1992 Jul;66(7):4464–4469. [PMC free article] [PubMed]
  • Brunda MJ, Minden P, Sharpton TR, McClatchy JK, Farr RS. Precipitation of radiolabeled antigen-antibody complexes with protein A-containing Staphylococcus aureus. J Immunol. 1977 Jul;119(1):193–198. [PubMed]
  • Burns DP, Desrosiers RC. Selection of genetic variants of simian immunodeficiency virus in persistently infected rhesus monkeys. J Virol. 1991 Apr;65(4):1843–1854. [PMC free article] [PubMed]
  • Burns DP, Desrosiers RC. A caution on the use of SIV/HIV gag antigen detection systems in neutralization assays. AIDS Res Hum Retroviruses. 1992 Jun;8(6):1189–1192. [PubMed]
  • Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res. 1987 Feb 15;47(4):936–942. [PubMed]
  • Daniel MD, Letvin NL, Sehgal PK, Hunsmann G, Schmidt DK, King NW, Desrosiers RC. Long-term persistent infection of macaque monkeys with the simian immunodeficiency virus. J Gen Virol. 1987 Dec;68(Pt 12):3183–3189. [PubMed]
  • Denizot F, Lang R. Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J Immunol Methods. 1986 May 22;89(2):271–277. [PubMed]
  • Dubois-Dalcq M, Narayan O, Griffin DE. Cell surface changes associated with mutation of visna virus in antibody-treated cell cultures. Virology. 1979 Jan 30;92(2):353–366. [PubMed]
  • Ellis TM, Wilcox GE, Robinson WF. Antigenic variation of caprine arthritis-encephalitis virus during persistent infection of goats. J Gen Virol. 1987 Dec;68(Pt 12):3145–3152. [PubMed]
  • Gazdar AF, Carney DN, Bunn PA, Russell EK, Jaffe ES, Schechter GP, Guccion JG. Mitogen requirements for the in vitro propagation of cutaneous T-cell lymphomas. Blood. 1980 Mar;55(3):409–417. [PubMed]
  • Haigwood NL, Shuster JR, Moore GK, Lee H, Skiles PV, Higgins KW, Barr PJ, George-Nascimento C, Steimer KS. Importance of hypervariable regions of HIV-1 gp120 in the generation of virus neutralizing antibodies. AIDS Res Hum Retroviruses. 1990 Jul;6(7):855–869. [PubMed]
  • Homsy J, Meyer M, Levy JA. Serum enhancement of human immunodeficiency virus (HIV) infection correlates with disease in HIV-infected individuals. J Virol. 1990 Apr;64(4):1437–1440. [PMC free article] [PubMed]
  • Hoxie JA, Haggarty BS, Bonser SE, Rackowski JL, Shan H, Kanki PJ. Biological characterization of a simian immunodeficiency virus-like retrovirus (HTLV-IV): evidence for CD4-associated molecules required for infection. J Virol. 1988 Aug;62(8):2557–2568. [PMC free article] [PubMed]
  • Kanki PJ, McLane MF, King NW, Jr, Letvin NL, Hunt RD, Sehgal P, Daniel MD, Desrosiers RC, Essex M. Serologic identification and characterization of a macaque T-lymphotropic retrovirus closely related to HTLV-III. Science. 1985 Jun 7;228(4704):1199–1201. [PubMed]
  • Kestler H, Kodama T, Ringler D, Marthas M, Pedersen N, Lackner A, Regier D, Sehgal P, Daniel M, King N, et al. Induction of AIDS in rhesus monkeys by molecularly cloned simian immunodeficiency virus. Science. 1990 Jun 1;248(4959):1109–1112. [PubMed]
  • Kestler HW, 3rd, Li Y, Naidu YM, Butler CV, Ochs MF, Jaenel G, King NW, Daniel MD, Desrosiers RC. Comparison of simian immunodeficiency virus isolates. Nature. 1988 Feb 18;331(6157):619–622. [PubMed]
  • Kestler HW, 3rd, Ringler DJ, Mori K, Panicali DL, Sehgal PK, Daniel MD, Desrosiers RC. Importance of the nef gene for maintenance of high virus loads and for development of AIDS. Cell. 1991 May 17;65(4):651–662. [PubMed]
  • Kodama T, Burns DP, Silva DP, Veronese FD, Desrosiers RC. Strain-specific neutralizing determinant in the transmembrane protein of simian immunodeficiency virus. J Virol. 1991 Apr;65(4):2010–2018. [PMC free article] [PubMed]
  • Kono Y, Kobayashi K, Fukunaga Y. Serological comparison among various strains of equine infectious anemia virus. Arch Gesamte Virusforsch. 1971;34(3):202–208. [PubMed]
  • Kono Y, Kobayashi K, Fukunaga Y. Antigenic drift of equine infectious anemia virus in chronically infected horses. Arch Gesamte Virusforsch. 1973;41(1):1–10. [PubMed]
  • Lasky LA, Nakamura G, Smith DH, Fennie C, Shimasaki C, Patzer E, Berman P, Gregory T, Capon DJ. Delineation of a region of the human immunodeficiency virus type 1 gp120 glycoprotein critical for interaction with the CD4 receptor. Cell. 1987 Sep 11;50(6):975–985. [PubMed]
  • Layne SP, Merges MJ, Spouge JL, Dembo M, Nara PL. Blocking of human immunodeficiency virus infection depends on cell density and viral stock age. J Virol. 1991 Jun;65(6):3293–3300. [PMC free article] [PubMed]
  • Leis J, Baltimore D, Bishop JM, Coffin J, Fleissner E, Goff SP, Oroszlan S, Robinson H, Skalka AM, Temin HM, et al. Standardized and simplified nomenclature for proteins common to all retroviruses. J Virol. 1988 May;62(5):1808–1809. [PMC free article] [PubMed]
  • Lutley R, Pétursson G, Pálsson PA, Georgsson G, Klein J, Nathanson N. Antigenic drift in visna: virus variation during long-term infection of Icelandic sheep. J Gen Virol. 1983 Jul;64(Pt 7):1433–1440. [PubMed]
  • McKeating JA, McKnight A, Moore JP. Differential loss of envelope glycoprotein gp120 from virions of human immunodeficiency virus type 1 isolates: effects on infectivity and neutralization. J Virol. 1991 Feb;65(2):852–860. [PMC free article] [PubMed]
  • Meyerhans A, Dadaglio G, Vartanian JP, Langlade-Demoyen P, Frank R, Asjö B, Plata F, Wain-Hobson S. In vivo persistence of a HIV-1-encoded HLA-B27-restricted cytotoxic T lymphocyte epitope despite specific in vitro reactivity. Eur J Immunol. 1991 Oct;21(10):2637–2640. [PubMed]
  • Montefiori DC, Zhou IY, Barnes B, Lake D, Hersh EM, Masuho Y, Lefkowitz LB., Jr Homotypic antibody responses to fresh clinical isolates of human immunodeficiency virus. Virology. 1991 Jun;182(2):635–643. [PubMed]
  • Montelaro RC, Parekh B, Orrego A, Issel CJ. Antigenic variation during persistent infection by equine infectious anemia virus, a retrovirus. J Biol Chem. 1984 Aug 25;259(16):10539–10544. [PubMed]
  • Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983 Dec 16;65(1-2):55–63. [PubMed]
  • Naidu YM, Kestler HW, 3rd, Li Y, Butler CV, Silva DP, Schmidt DK, Troup CD, Sehgal PK, Sonigo P, Daniel MD, et al. Characterization of infectious molecular clones of simian immunodeficiency virus (SIVmac) and human immunodeficiency virus type 2: persistent infection of rhesus monkeys with molecularly cloned SIVmac. J Virol. 1988 Dec;62(12):4691–4696. [PMC free article] [PubMed]
  • Nara PL, Smit L, Dunlop N, Hatch W, Merges M, Waters D, Kelliher J, Gallo RC, Fischinger PJ, Goudsmit J. Emergence of viruses resistant to neutralization by V3-specific antibodies in experimental human immunodeficiency virus type 1 IIIB infection of chimpanzees. J Virol. 1990 Aug;64(8):3779–3791. [PMC free article] [PubMed]
  • Narayan O, Clements JE, Griffin DE, Wolinsky JS. Neutralizing antibody spectrum determines the antigenic profiles of emerging mutants of visna virus. Infect Immun. 1981 Jun;32(3):1045–1050. [PMC free article] [PubMed]
  • Narayan O, Griffin DE, Chase J. Antigenic shift of visna virus in persistently infected sheep. Science. 1977 Jul 22;197(4301):376–378. [PubMed]
  • Narayan O, Griffin DE, Clements JE. Virus mutation during 'slow infection': temporal development and characterization of mutants of visna virus recovered from sheep. J Gen Virol. 1978 Nov;41(2):343–352. [PubMed]
  • Narayan O, Griffin DE, Silverstein AM. Slow virus infection: replication and mechanisms of persistence of visna virus in sheep. J Infect Dis. 1977 May;135(5):800–806. [PubMed]
  • Narayan O, Sheffer D, Griffin DE, Clements J, Hess J. Lack of neutralizing antibodies to caprine arthritis-encephalitis lentivirus in persistently infected goats can be overcome by immunization with inactivated Mycobacterium tuberculosis. J Virol. 1984 Feb;49(2):349–355. [PMC free article] [PubMed]
  • Payne S, Parekh B, Montelaro RC, Issel CJ. Genomic alterations associated with persistent infections by equine infectious anaemia virus, a retrovirus. J Gen Virol. 1984 Aug;65(Pt 8):1395–1399. [PubMed]
  • Payne SL, Fang FD, Liu CP, Dhruva BR, Rwambo P, Issel CJ, Montelaro RC. Antigenic variation and lentivirus persistence: variations in envelope gene sequences during EIAV infection resemble changes reported for sequential isolates of HIV. Virology. 1987 Dec;161(2):321–331. [PubMed]
  • Pétursson G, Nathanson N, Georgsson G, Panitch H, Pálsson PA. Pathogenesis of visna. I. Sequential virologic, serologic, and pathologic studies. Lab Invest. 1976 Oct;35(4):402–412. [PubMed]
  • Phillips RE, Rowland-Jones S, Nixon DF, Gotch FM, Edwards JP, Ogunlesi AO, Elvin JG, Rothbard JA, Bangham CR, Rizza CR, et al. Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition. Nature. 1991 Dec 12;354(6353):453–459. [PubMed]
  • Regier DA, Desrosiers RC. The complete nucleotide sequence of a pathogenic molecular clone of simian immunodeficiency virus. AIDS Res Hum Retroviruses. 1990 Nov;6(11):1221–1231. [PubMed]
  • Robertson GA, Kostek BM, Schleif WA, Lewis JA, Emini EA. A microtiter cell-culture assay for the determination of anti-human immunodeficiency virus neutralizing antibody activity. J Virol Methods. 1988 Jul;20(3):195–202. [PubMed]
  • Salinovich O, Payne SL, Montelaro RC, Hussain KA, Issel CJ, Schnorr KL. Rapid emergence of novel antigenic and genetic variants of equine infectious anemia virus during persistent infection. J Virol. 1986 Jan;57(1):71–80. [PMC free article] [PubMed]
  • Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A. 1977 Dec;74(12):5463–5467. [PubMed]
  • Starcich BR, Hahn BH, Shaw GM, McNeely PD, Modrow S, Wolf H, Parks ES, Parks WP, Josephs SF, Gallo RC, et al. Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III/LAV, the retrovirus of AIDS. Cell. 1986 Jun 6;45(5):637–648. [PubMed]
  • Thormar H, Barshatzky MR, Arnesen K, Kozlowski PB. The emergence of antigenic variants is a rare event in long-term visna virus infection in vivo. J Gen Virol. 1983 Jul;64(Pt 7):1427–1432. [PubMed]
  • Tremblay M, Wainberg MA. Neutralization of multiple HIV-1 isolates from a single subject by autologous sequential sera. J Infect Dis. 1990 Sep;162(3):735–737. [PubMed]
  • Veronese FD, Joseph B, Copeland TD, Oroszlan S, Gallo RC, Sarngadharan MG. Identification of simian immunodeficiency virus SIVMAC env gene products. J Virol. 1989 Mar;63(3):1416–1419. [PMC free article] [PubMed]
  • Von Gegerfelt A, Albert J, Morfeldt-Månson L, Broliden K, Fenyö EM. Isolate-specific neutralizing antibodies in patients with progressive HIV-1-related disease. Virology. 1991 Nov;185(1):162–168. [PubMed]
  • Weiss RA, Clapham PR, Weber JN, Dalgleish AG, Lasky LA, Berman PW. Variable and conserved neutralization antigens of human immunodeficiency virus. Nature. 1986 Dec 11;324(6097):572–575. [PubMed]

Articles from Journal of Virology are provided here courtesy of American Society for Microbiology (ASM)